Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus

Journal of Rheumatology

Volumn 29, Issue 10, 2002, Pages 2129-2135

  Ioannidis, John P A ^a   Katsifis, Gikas E ^a   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Amenorrhea; Intravenous cyclophosphamide; Predictive model; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; PROTEIN ANTIBODY;

ADULT; AGE; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AMENORRHEA; ANTIRHEUMATIC AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; GREECE; HUMANS; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PULSE THERAPY, DRUG; RISK FACTORS;

EID: 0036791907     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001;10:154-61.
2. Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
3. Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
4. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide induced ovarian failure. N Engl J Med 1973;289:1159-62.
5. Kumar R, Biggart JD, McEvoy J, McGeown MG. Cyclophosphamide and reproductive function. Lancet 1972;i:1212-4.
6. Uldall PR, Kerr DNS, Tacchi D. Sterility in cyclophosphamide. Lancet 1972;i:693-4.
7. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992;28:157-8.
8. Belmont HM, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995;4:104-8.
9. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
10. D'Cruz D, Cuadrado MJ, Mujic F, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997;15:275-82.
11. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995;4:11-4.
12. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996;55:224-9.
13. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
14. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
15. Ioannidis JPA, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
16. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
17. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000;9:445-50.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall; 1984.
20. Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for lupus nephritis. Lancet 1999;354:569-70.
21. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
22. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999;42:1274-80.
23. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999;8:3-10.
24. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72.
25. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-5.
26. Ataya KM, Pydyn E, Young J, Struck R. The uptake and metabolism of cyclophosphamide by the ovary. Sel Cancer Ther 1990;6:83-92.
27. Ataya KM, Valeriote FA, Ramahi-Ataya A. Effects of cyclophosphamide on immature rat ovary. Cancer Res 1989;49:1660-4.
28. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.
29. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994;20:87-118.
30. Pasoto SG, Vianna VS, Mendonca BB, et al. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus. J Rheumatol 1999;26:1087-93.
31. Moncayo R, Moncayo HE. A new endocrinological and immunological syndrome in SLE: elevation of human chorionic gonadotropin and of antibodies directed against ovary and endometrium antigens. Lupus 1995;4:39-45.
32. Luborsky J, Llanes B, Davies S, et al. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin Immunol 1999;90:368-74.
33. Ishizuka B, Kudo Y, Amemiya A, et al. Anti-nuclear antibodies in patients with premature ovarian failure. Hum Reprod 1999;14:70-5.
34. Mavragani CP, Ioannidis JPA, Tzioufas AG, et al. Recurrent pregnancy loss and autoantibody profile in autoimmune diseases. Rheumatology 1999;38:1228-33.
35. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994;120:544-51.
36. Sheth AP, Esterly NB, Rattosh SL, et al. U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? Br J Dermatol 1995;132:520-6.
37. Reichlin M, Harley JB. Immune response to the RNA protein particles in systemic lupus erythematosus. A distinctive dichotomy. Am J Med 1988;85:35-7.
38. Deshmukh US, Lewis JE, Gaskin F, et al. Ro60 peptides induce antibodies to similar epitopes shared among lupus-related autoantigens. J Immunol 2000;164:6655-61.